Offering expertise for EIC Pathfinder Challenge - Emerging Technologies in Cell & Gene Therapy
We are posting this opportunity to help institutions in finding the right European academic partner for their consortium. Our research infrastructure is composed of 110 research institutes across 13 countries.
For this particular call, EATRIS members can offer the following expertise:
- Expertise in cell therapy and genome editing products in targeted cells and tissues (e.g., base editing, prime editing, talens, zinc-finger nucleases, CRISPR).
- Expertise in novel RNA-based therapeutics
- Expertise in in gene delivery vehicles using next generation AAV or other recombinant vectors
- Expertise in upscaling and GMP product development of advanced therapies in cell and gene therapies and vector production
- Clinical trial centres for phase I/II studies in conjunction with a university medical centre to foster interaction between clinicians and specialist scientists.
- Support for trial design and GCP execution.
- Advanced technologies for disease specific research including cancer organoids, organ on a chip to test responses to different ATMPs.
- Multimodal Imaging approaches to track cells to measure biodistribution and efficacy of immunotherapies including nanoparticle approaches, PET-CT, PET-MRI
- In vivo Imaging Technologies to Monitor the Immune System - Mass Cytometry Imaging (MCI), PET-CT, PET-MRI, US modalities for studies of the immune system response
- Data analysis centres manage the processing and integration of multi- modality data.
- Regulatory Services- Scientific Advice, TPP and IMPD development
- Access to 3D culture systems; patient-derived organoids; patient-derived xenografts, Spheroids and Multifluidic Devices for Immune surveillance in TME for ATMP products
- Epigenetics of immune cells to study genome-wide epigenetic changes including DNA methylation, histone modifications and non-coding RNAs expression
- Multiomics (epigenomic, transcriptomic, proteomic, metabolomics, study of the microbiome and virome, etc.) to assess functional characteristics of TME-tumour cell interplay within the primary tumour and/or metastases (e.g the underlying signaling, the transcriptional landscape, the cell-cell communication, the network regulation of immune cells, etc.), to identify candidate TME targets and to assess the activity of pathway-targeting agents
- Immune profiling – Systems level characterization of immune cells in human tissues (multi-parametric flow cytometry, mass cytometry [CyTOF], Helios) and Immune assays (in vitro functional immune assays, high-throughput multiplex immunoassay)
- Bioinformatics and Data Center
In vivo models:
- Humanized mouse models (e.g., patient-derived xenograft; immuno-Avatar)
- Immunocompetent and genetically engineered mouse models
- Non-human primates and other species
- Development of adequate potency tests.
- Pre-clinical in vivo validation in disease specific animal models including primates
- Pre-clinical evaluation of ATMP immunogenicity, efficacy and toxicology.
- Access to collaborative network to provide a framework for hiPSC generation of hiPSC homozygous for frequent HLA haplotypes.